[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk (NVO), which makes Ozempic and Wegovy (for weight loss and Type 2 diabetes). NVO stock has been moving up, so is it overvalued now?

NVO is at $49.23 in midday trading on July 1, up over 2.6%. In the past 4 weeks, NVO has risen 20% from its low point on June 8 ($41.02).

Fundamentals

See More
  • Market Capitalization, $K 214,052,096
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 23,190 M
  • EBITDA $ 26,518 M
  • 60-Month Beta 0.78
  • Price/Sales 4.61
  • Price/Cash Flow 10.31
  • Price/Book 6.79

Options Overview Details

View History
  • Implied Volatility 41.79% (+0.61%)
  • Historical Volatility 35.16%
  • IV Percentile 35%
  • IV Rank 21.95%
  • IV High 64.20% on 10/09/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 9) 1.75 (3.59%)
  • Put/Call Vol Ratio 0.66
  • Today's Volume 59,735
  • Volume Avg (30-Day) 60,882
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 1,332,209
  • Open Int (30-Day) 1,406,909
  • Expected Range 47.02 to 50.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.82
  • Number of Estimates 5
  • High Estimate $0.87
  • Low Estimate $0.77
  • Prior Year $0.97
  • Growth Rate Est. (year over year) -15.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.00 +18.95%
on 06/08/26
49.55 -1.57%
on 07/01/26
+4.70 (+10.66%)
since 06/01/26
3-Month
35.63 +36.90%
on 04/02/26
49.55 -1.57%
on 07/01/26
+12.29 (+33.69%)
since 04/01/26
52-Week
35.12 +38.87%
on 03/30/26
71.79 -32.07%
on 07/25/25
-21.05 (-30.15%)
since 07/01/25

Most Recent Stories

More News
Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk, which makes Ozempic and Wegovy. NVO stock has been moving up, so is it overvalued now?

NVO : 48.77 (+1.73%)
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

TDOC : 9.10 (+7.31%)
NVO : 48.77 (+1.73%)
OZEM : 32.39 (-0.46%)
LLY : 1,191.74 (-0.64%)
DXCM : 68.86 (+2.24%)
OLLI : 75.51 (-1.78%)
These 3 Quality Stocks Will Make You Want to LEAP on Their Calls

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks...

SBUX : 103.39 (+1.17%)
NVO : 48.77 (+1.73%)
LLY : 1,191.74 (-0.64%)
PFE : 23.88 (-0.83%)
AMZN : 241.70 (+1.41%)
DIS : 95.71 (-0.56%)
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

CVS : 104.81 (+1.31%)
CI : 277.07 (+0.50%)
NVO : 48.77 (+1.73%)
LLY : 1,191.74 (-0.64%)
UNH : 426.54 (+2.62%)
5 Best Growth Stocks for the Next 10 Years

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

MELI : 1,742.19 (+2.64%)
AAPL : 294.38 (+1.73%)
AVGO : 369.34 (-2.23%)
NVO : 48.77 (+1.73%)
LLY : 1,191.74 (-0.64%)
NET : 246.31 (+0.42%)
TSM : 444.23 (-6.98%)
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

HIMS : 37.57 (+8.36%)
NVO : 48.77 (+1.73%)
LLY : 1,191.74 (-0.64%)
ABBV : 251.06 (-0.23%)
Why Wall Street Thinks This Dividend Stock Could Jump 30%

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

NVO : 48.77 (+1.73%)
LLY : 1,191.74 (-0.64%)
AMGN : 361.33 (-0.22%)
The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

HIMS : 37.57 (+8.36%)
NVO : 48.77 (+1.73%)
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

MMA : 0.5400 (+4.65%)
BPC.CN : 0.4800 (-1.03%)
PNGAF : 0.3494 (+4.49%)
NVO : 48.77 (+1.73%)
HIMS : 37.57 (+8.36%)
LLY : 1,191.74 (-0.64%)
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness,...

MMA : 0.5400 (+4.65%)
BPC.CN : 0.4800 (-1.03%)
PNGAF : 0.3494 (+4.49%)
NVO : 48.77 (+1.73%)
HIMS : 37.57 (+8.36%)
LLY : 1,191.74 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 50.28
2nd Resistance Point 49.92
1st Resistance Point 49.34
Last Price 48.77
1st Support Level 48.40
2nd Support Level 48.04
3rd Support Level 47.47

See More

52-Week High 71.79
Fibonacci 61.8% 57.79
Fibonacci 50% 53.46
Fibonacci 38.2% 49.13
Last Price 48.77
52-Week Low 35.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.